The STOP-PKD study is investigating a new treatment option for people with autosomal dominant polycystic kidney disease (ADPKD). The study aims to determine whether an already approved medication from the class of so-called SGLT2 inhibitors (dapagliflozin) can have a positive effect on the course of ADPKD.
Rotterdam- Start of the 2nd Dutch trial site
on Jul 16, 2026 at 10:04 AM
University Hospital Charité Berlin- New Principal Investigator
on Jun 19, 2026 at 08:59 AM
Düsseldorf- Start of a new trial site
on Jun 19, 2026 at 08:57 AM
University Hospital Cologne- New Principal Investigator
on Jun 19, 2026 at 08:46 AM
Munich - Start of a new trial site (TUM)
on Jun 15, 2026 at 09:22 AM
Innsbruck- Start of the 1st Austrian trial site
on Jun 12, 2026 at 07:44 AM
Klinikum Stuttgart- New Principal Investigator
on Jun 08, 2026 at 11:44 AM
Stuttgart- Start of a new trial site
on May 26, 2026 at 10:47 AM
LMU Munich- Start of a new trial site
on Apr 13, 2026 at 08:45 AM
Groningen- Start of the 1st Dutch trial site
on Apr 08, 2026 at 08:18 AM
Frankfurt - Start of a new trial site
on Apr 02, 2026 at 10:15 AM